Rheumatoid arthritis (RA) has a significant genetic component, with heritability estimated at about 60%. But genetics alone don’t determine whether you’ll develop the disease. Identical twins, who share 100% of their DNA, only both develop RA about 15% of the time, meaning environmental factors and other biological changes play a major role alongside your genes.
How Much of RA Risk Is Inherited?
If you have a first-degree relative with RA (a parent, sibling, or child), your risk of developing the disease is roughly three to five times higher than someone without that family history. The closer the relative, the higher the risk: first-degree relatives face greater odds than second-degree relatives like aunts, uncles, or grandparents.
Twin studies help separate genetic influence from shared environment. A nationwide study found that 15.4% of identical twin pairs were both affected by RA, compared to just 3.6% of fraternal twin pairs. That fourfold difference confirms a real genetic contribution. But the fact that 85% of identical twins don’t share the diagnosis tells an equally important story: inheriting RA-related genes is far from a guarantee.
The Most Important Genetic Risk Factor
The single biggest genetic driver of RA is a gene called HLA-DRB1, which sits within a region of your genome responsible for helping your immune system distinguish your own tissues from foreign invaders. Certain variants of this gene share a common structural feature known as the “shared epitope,” and carrying one or two copies of these variants substantially raises your risk. One specific variation at a single position in the gene increases RA risk by nearly fourfold.
Here’s what these variants actually do in your body. The HLA-DRB1 gene provides instructions for building a protein that sits on the surface of immune cells and presents small fragments of proteins to other immune cells, essentially flagging them for inspection. In people with shared epitope variants, this protein develops a positively charged pocket that is especially good at grabbing onto citrullinated proteins. Citrullination is a normal chemical modification that happens to proteins throughout your body, but in people with these gene variants, the immune system is more likely to mistake citrullinated proteins for threats and launch an attack against them.
This triggers the production of anti-citrullinated protein antibodies (sometimes called anti-CCP antibodies on lab tests), which are found in roughly 60 to 70% of RA patients and are one of the hallmarks of the disease. These antibodies can be detected in the blood years before symptoms appear, and as they mature and diversify, they eventually contribute to the joint inflammation and damage characteristic of RA.
Other Genes That Contribute
Beyond HLA-DRB1, dozens of other genes each add a small amount of risk. The most influential of these is PTPN22, which is considered the most important non-HLA gene in autoimmune disease. PTPN22 acts as a brake on your immune system, helping regulate how strongly your T cells and B cells respond to signals. A specific variant of this gene weakens that braking function. It also disrupts the gene’s ability to bind to an enzyme involved in citrullination, potentially increasing the production of citrullinated proteins that the immune system then attacks.
Other genes linked to RA play roles in immune signaling, inflammation, and the behavior of immune cells, but individually each one contributes only a modest increase in risk. The cumulative effect of carrying multiple risk variants across many genes is what matters.
Genetic Risk Varies by Ethnicity
The specific genes that drive RA risk differ across populations. The PTPN22 variant, for example, is a major risk factor in people of European ancestry but is rarely found in Asian populations. Conversely, a gene called PADI4, which is directly involved in the citrullination process, is a stronger risk factor in Japanese and other East Asian populations.
The HLA-DRB1 gene matters across all ethnic groups, but which specific subtypes of the gene are associated with RA varies between populations. This genetic heterogeneity helps explain why RA prevalence, severity, and antibody patterns can look different across geographic and ethnic groups.
Why Genetics Isn’t the Whole Story
The 12 to 15% concordance rate in identical twins makes a strong case that something beyond DNA sequence is needed to trigger RA. Two major categories fill the gap: environmental exposures and epigenetic changes.
Epigenetics refers to chemical modifications that sit on top of your DNA and control whether specific genes are turned on or off, without changing the underlying genetic code. In people with RA, researchers have found widespread changes in these modifications, particularly in immune cells and in the cells lining the joints. Key genes involved in inflammation, including those controlling major inflammatory signals like IL-6, show altered patterns. Unlike genetic mutations, these epigenetic changes are reversible and are sensitive to environmental influences, which is part of why they’re an active area of treatment research.
How Smoking Multiplies Genetic Risk
The best-studied example of a gene-environment interaction in RA involves smoking. On its own, carrying shared epitope variants raises your risk. Smoking on its own also raises your risk. But the combination does something more than simply add those risks together: it multiplies them, particularly for the antibody-positive form of RA.
In people who are positive for both major RA antibody types, smoking and the shared epitope interact strongly, with the risk climbing further as the number of shared epitope copies increases from one to two. The effect also grows with heavier smoking exposure. People who carry two copies of the shared epitope and have a significant smoking history face dramatically higher odds than those with only one risk factor. This interaction is strongest in the subset of RA that produces anti-CCP antibodies, which is also the form most tightly linked to HLA-DRB1 variants.
Smoking is thought to promote citrullination of proteins in the lungs, creating more of the very targets that shared epitope variants are primed to flag for immune attack. This creates a feedback loop where genetic susceptibility and environmental exposure reinforce each other.
What This Means for Your Risk
Having a family history of RA, particularly in a parent or sibling, is the most practical signal that you may carry genetic risk. But the overall picture is reassuring in one important respect: most people with RA-associated genes never develop the disease. The 60% heritability estimate means genetics sets the stage, but environmental factors, epigenetic changes, hormonal influences, and likely some element of chance determine whether the disease actually develops.
If RA runs in your family, the most actionable step you can take based on current evidence is to avoid smoking, given the well-documented interaction between smoking and genetic susceptibility. Maintaining awareness of early symptoms, particularly persistent joint stiffness and swelling lasting more than six weeks, matters because early treatment significantly improves long-term outcomes.